Please login to the form below

Not currently logged in
Email:
Password:

financial results

This page shows the latest financial results news and features for those working in and with pharma, biotech and healthcare.

Lilly’s Trulicity scores CV reduction indication in the US

Lilly’s Trulicity scores CV reduction indication in the US

The results also showed that Trulicity demonstrated consistent MACE risk reduction across major demographic and disease subgroups. ... In its most recent financial results, Lilly reported that Trulicity (dulaglutide) grew by nearly 31% to bring in

Latest news

More from news
Approximately 70 fully matching, plus 121 partially matching documents found.

Latest Intelligence

  • Deal Watch - May 2017 Deal Watch - May 2017

    some financial companies to re-emerge as Barbarians.  The 2008 financial crash is a salutary reminder. ... What happens next?    Assuming the deal is completed, DW predicts the new Stada will start to hunt for product and company acquisitions to

  • Deal Watch August 2016 Deal Watch August 2016

    company rather than seeking a short term financial 'fix' to improve its financial results.”. ... In the same way that the asset acquisition deal between AstraZeneca and Pfizer had the financial structure of a licence, so too does the Pfizer acquisition

  • Technology: the missing link in true patient engagement? Technology: the missing link in true patient engagement?

    This comes at a huge financial cost, and results in suboptimal patient outcomes. ... While manual adherence programmes with assigned nurses have yielded positive outcomes, it isn't always possible to provide this widely due to financial and resource

  • Deal Watch April 2016 Deal Watch April 2016

    term financial 'fix' to improve its financial results. ... The deal with Nimbus did not excite investors and they were even less impressed when Gilead reported first quarter results showing sales growth of 4% and full year guidance of $30bn

  • Who tops the pharma list? Who tops the pharma list?

    Chris Ross, with the help of healthcare analysts GlobalData, takes a New Year look at the past, present and future of global pharma, and asks: what’s trending? 

More from intelligence
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics